












Whole-Genome Sequences of *Burkholderia pseudomallei* Isolates Exhibiting Decreased Meropenem Susceptibility

 Erin P. Price,^{a,b}  Melissa Laird Smith,^{c*}  Ellen E. Paxinos,^{c*}  Luke J. Tallon,^d  Lisa Sadzewicz,^d  Naomi Sengamalay,^{d*}  Robert W. Baird,^{e,f}  Bart J. Currie,^{a,e}  Derek S. Sarovich^{a,b}

Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia^a; Centre for Animal Health Innovation, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sippy Downs, Queensland, Australia^b; Pacific Biosciences, Menlo Park, California, USA^c; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA^d; Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia^e; Pathology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia^f

ABSTRACT We report here paired isogenic *Burkholderia pseudomallei* genomes obtained from three patients receiving intravenous meropenem for melioidosis treatment, with post-meropenem isolates developing decreased susceptibility. Two genomes were finished, and four were drafted to improved high-quality standard. These genomes will be used to identify meropenem resistance mechanisms in *B. pseudomallei*.

B*urkholderia pseudomallei* is a Gram-negative soil- and water-borne bacterium that causes the tropical infectious disease melioidosis. Melioidosis severity ranges widely, with the most serious form of disease, septic shock, resulting in fatality in up to 95% of untreated cases (1). *B. pseudomallei* is intrinsically resistant to many antibiotics commonly used in sepsis treatment, limiting treatment options and often resulting in progressive disease when not diagnosed (2, 3). In Australia, where melioidosis mortality rates have decreased to approximately 10% (4), ceftazidime is the mainstay of intravenous therapy for melioidosis, with meropenem usually reserved for life-threatening sepsis requiring intensive care therapy (5). We recently identified three Australian blood culture-persistent patients in whom decreased meropenem sensitivity has been observed (D.S. Sarovich, J. R. Webb, M. C. Pitman, L. Viberg, M. Mayo, R. W. Baird, B. J. Currie, E. P. Price, unpublished data); this is the first time that this phenomenon has been reported. Identifying the molecular mechanisms underpinning decreased meropenem susceptibility in *B. pseudomallei* is vital in detecting resistance emergence toward this life-saving antibiotic. The genome of another clinical isolate of *B. pseudomallei* with imipenem resistance, a related carbapenem, has recently been described (6).

Three paired isogenic *B. pseudomallei* isolates were examined in this study (Table 1). The first isolates were sensitive toward meropenem, whereas the latter isolates had decreased sensitivity according to MIC testing. The six isolates were extracted as previously described (7), with the addition of RNase treatment. Genomic DNA was subjected to Illumina paired-end HiSeq2000 whole-genome sequencing (Macrogen Inc., Geumcheon-gu, Seoul, Republic of Korea) to ~55× coverage. In addition, PacBio single-molecule real-time sequencing was conducted on the PacBio RS II instrument (Institute for Genome Sciences, Baltimore, MD, USA) to ~13× coverage using 20-kb SMRTbell libraries and P6C4 chemistry.

Received 19 January 2017 **Accepted** 2 February 2017 **Published** 6 April 2017

Citation Price EP, Smith ML, Paxinos EE, Tallon LJ, Sadzewicz L, Sengamalay N, Baird RW, Currie BJ, Sarovich DS. 2017. Whole-genome sequences of *Burkholderia pseudomallei* isolates exhibiting decreased meropenem susceptibility. *Genome Announc* 5:e00053-17. <https://doi.org/10.1128/genomeA.00053-17>.

Copyright © 2017 Price et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Erin P. Price, epprice@usc.edu.au.

* Present address: Melissa Laird Smith, Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Ellen E. Paxinos, Roche Molecular Systems, Pleasanton, California, USA; Naomi Sengamalay, Personal Genome Diagnostics, Baltimore, Maryland, USA.

TABLE 1 Isogenic *B. pseudomallei* strains sequenced in this study

Strain pair ^a	Multilocus sequence type ^b	No. of contigs (status) ^c	Genome size in bp (% GC content)	GenBank and/or SRA accession no.
MSHR3763	36	2 (finished)	7,437,013 (67.9)	CP017052, CP017053; SRS1143371
MSHR4083	36	2 (finished)	7,437,071 (67.9)	CP017050, CP017051; SRS1143382
MSHR5864	975	2 (IHQD ^d)	7,317,380 (68.1)	CP017048, CP017049
MSHR6755	975	2 (IHQD ^d)	7,300,607 (68.1)	CP017046, CP017047
MSHR6522	437	3 (IHQD ^{d,e})	7,285,806 (68.2)	MECZ00000000
MSHR7929	437	2 (finished)	7,248,498 (68.2)	CP017044, CP017045

^aThe latter strain from each pair has decreased sensitivity to meropenem.

^bBased on the scheme at <http://pubmlst.org/bpseudomallei>.

^cAssembly definitions according to Chain et al. (14). IHQD, improved high-quality draft.

^dTrimming of chromosome 1 was not possible due to overlap issues.

^eThe third contig aligns to the end of chromosome 1.

PacBio genomic data were assembled using HGAP.3 (8) (MSHR strains 3763, 4083, and 5864), Celera Assembler version 8.2 (9) (MSHR strain 6522), and Celera Assembler version 8.3 (MSHR strains 6755 and 7929). Assemblies were reorganized relative to the closed *B. pseudomallei* K96243 genome (10) (GenBank accession no. CP009538 and CP009537) with the assistance of progressiveMAUVE (11), followed by error-correction with the Illumina reads using iCORN2 (12). For MSHR strains 3763 and 4083, SPANDx version 3.1 (13) was used to identify a handful of remaining errors in the assemblies, which were manually corrected and verified by repeat analysis in SPANDx. All variants were also confirmed by comparison of the MSHR strain 3763 and MSHR strain 4083 assemblies using Illumina-only assemblies generated by MGAP.

The development of *B. pseudomallei* resistance toward meropenem is of great concern, as this drug is one of a handful of efficacious antimicrobials for melioidosis treatment. Meropenem resistance is especially concerning given that this antibiotic is used to treat the most severe melioidosis cases in Australia and some other melioidosis-endemic regions. Treatment failure in such cases must be rapidly identified in the clinical setting to enable clinicians to alter therapy in close-to-real time. The six genomes reported in this study will be used to search for genetic variants imparting decreased meropenem susceptibility in *B. pseudomallei*.

Accession number(s). The genome sequences of the *B. pseudomallei* isolates reported here have been deposited in GenBank under the accession numbers listed in Table 1.

ACKNOWLEDGMENTS

We thank the Microbiology Laboratory scientists at Royal Darwin Hospital and Mark Mayo and Vanessa Theobald for isolate identification and laboratory assistance. Funding for this project was provided by the Australian National Health and Medical Research Council via awards 1046812 and 1098337, with the PacBio sequencing funded by the Pacific Biosciences SMRTTest Microbe 2015 Grant Program, of which E.P.P. was the recipient. E.P.P. was funded by a USC Research Fellowship. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

- Cheng AC, Stephens DP, Anstey NM, Currie BJ. 2004. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. *Clin Infect Dis* 38:32–37. <https://doi.org/10.1086/380456>.
- Wuthiekanun V, Amornchai P, Saiprom N, Chantratita N, Chierakul W, Koh GC, Chaowagul W, Day NP, Limmathurotsakul D, Peacock SJ. 2011. Survey of antimicrobial resistance in clinical *Burkholderia pseudomallei* isolates over two decades in northeast Thailand. *Antimicrob Agents Chemother* 55:5388–5391. <https://doi.org/10.1128/AAC.05517-11>.
- Dance D. 2014. Treatment and prophylaxis of melioidosis. *Int J Antimicrob Agents* 43:310–318. <https://doi.org/10.1016/j.ijantimicag.2014.01.005>.
- Currie BJ. 2015. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. *Semin Respir Crit Care Med* 36:111–125. <https://doi.org/10.1055/s-0034-1398389>.
- Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. 2004. Outcomes of patients with melioidosis treated with meropenem. *Antimicrob Agents Chemother* 48:1763–1765.
- Bugrysheva JV, Sue D, Hakovirta J, Loparev VN, Knipe K, Sammons SA, Ranganathan-Ganakammal S, Changayil S, Srinivasamoorthy G, Weil MR, Tatusov RL, Gee JE, Elrod MG, Hoffmaster AR, Weigel LM. 2015. Finished annotated genome sequence of *Burkholderia pseudomallei* strain

- Bp1651, a multidrug-resistant clinical isolate. *Genome Announc* 3(6): e01427-15. <https://doi.org/10.1128/genomeA.01427-15>.
7. Currie BJ, Gal D, Mayo M, Ward L, Godoy D, Spratt BG, LiPuma JJ. 2007. Using BOX-PCR to exclude a clonal outbreak of melioidosis. *BMC Infect Dis* 7:68. <https://doi.org/10.1186/1471-2334-7-68>.
 8. Chin CS, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, Clum A, Copeland A, Huddleston J, Eichler EE, Turner SW, Korlach J. 2013. Non-hybrid, finished microbial genome assemblies from long-read SMRT sequencing data. *Nat Methods* 10:563–569. <https://doi.org/10.1038/nmeth.2474>.
 9. Myers EW, Sutton GG, Delcher AL, Dew IM, Fasulo DP, Flanigan MJ, Kravitz SA, Mobarry CM, Reinert KH, Remington KA, Anson EL, Bolanos RA, Chou HH, Jordan CM, Halpern AL, Lonardi S, Beasley EM, Brandon RC, Chen L, Dunn PJ, Lai Z, Liang Y, Nusskern DR, Zhan M, Zhang Q, Zheng X, Rubin GM, Adams MD, Venter JC. 2000. A whole-genome assembly of *Drosophila*. *Science* 287:2196–2204.
 10. Johnson SL, Bishop-Lilly KA, Ladner JT, Daligault HE, Davenport KW, Jaissle J, Frey KG, Koroleva GI, Bruce DC, Coyne SR, Broomall SM, Ketheesan N, Mayo M, Hoffmaster AR, Elrod MG, Wuthiekanun V, Tuan-yok A, Norton R, Currie BJ, Wagner DM, Keim P, Li PE, Teshima H, Gibbons HS, Palacios GF, Rosenzweig CN, Redden CL, Xu Y, Minogue TD, Chain PS. 2016. Correction for Johnson et al., Complete genome sequences for 59 *Burkholderia* isolates, both pathogenic and near neighbor. *Genome Announc* 4(2):e00313-16. <https://doi.org/10.1128/genomeA.00313-16>.
 11. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. *PLoS One* 5:e11147. <https://doi.org/10.1371/journal.pone.0011147>.
 12. Otto TD, Sanders M, Berriman M, Newbold C. 2010. Iterative correction of reference nucleotides (iCORN) using second generation sequencing technology. *Bioinformatics* 26:1704–1707. <https://doi.org/10.1093/bioinformatics/btq269>.
 13. Sarovich DS, Price EP. 2014. SPANDx: a genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. *BMC Res Notes* 7:618. <https://doi.org/10.1186/1756-0500-7-618>.
 14. Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, Ali J, Birren B, Bruce DC, Buhay C, Cole JR, Ding Y, Dugan S, Field D, Garrity GM, Gibbs R, Graves T, Han CS, Harrison SH, Highlander S, Hugenholtz P, Khouri HM, Kodira CD, Kolker E, Kyrpides NC, Lang D, Lapidus A, Malfatti SA, Markowitz V, Metha T, Nelson KE, Parkhill J, Pitluck S, Qin X, Read TD, Schmutz J, Sothamannan S, Sterk P, Strausberg RL, Sutton G, Thomson NR, Tiedje JM, Weinstock G, Wollam A, Consortium Genomic Standards Consortium Human Microbiome Project Jumpstart. 2009. Genome project standards in a new era of sequencing. *Science* 326:236–237. <https://doi.org/10.1126/science.1180614>.